Additional file 1 of Integrated DIA proteomics and lipidomics analysis on non-small cell lung cancer patients with TCM syndromes

Additional file 1: Figure S1. Quality control in the proteomics analysis. Figure S2. Venn analysis of differential proteins and lipids. Figure S3. PCA score plots of lipidomic analysis in plasma from human. Figure S4. Validation plots of the OPLS-DA models obtained using 200 permutation tests in plasma. Figure S5. Box plots for validation of ALDOC analyzed by ELISA. Table S1. Characteristics of the subjects. Table S2. List of TOF/MS parameters, Ionspray voltage floating (ISVF), The turbo spray temperature (TEM), Nebulizer gas (Gas 1), Heater gas (Gas 2), Curtain gas Declustering potential (DP), Collision energy in MS (CE in MS) and Collision energy in MS/MS (CE in MS/MS), Nebulizer and auxiliary gas, and scan range for positive and negative ionization mode. Table S5. Precision, repeatability and stability in the method validation of the plasma samples in positive mode. Table S6. Precision, repeatability and stability in the method validation of the plasma samples in negative mode. Table S7. The absolute values of correlation coefficients (|r|) between the proteomics results and the lipidomics results in NSCLC patients

Additional file 3 of Integrated DIA proteomics and lipidomics analysis on non-small cell lung cancer patients with TCM syndromes

Additional file 3: Table S4. Detailed information of GO and KEGG enrichment analysis

Additional file 2 of Integrated DIA proteomics and lipidomics analysis on non-small cell lung cancer patients with TCM syndromes

Additional file 2: Table S3. Significant differentially-expressed proteins in plasma of lung cancer patients